<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390559</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-11082-3</org_study_id>
    <secondary_id>R01DA011082</secondary_id>
    <secondary_id>R01-11082-3 DPMC</secondary_id>
    <nct_id>NCT00390559</nct_id>
  </id_info>
  <brief_title>Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3</brief_title>
  <official_title>Effects of Transdermal Nicotine on Tobacco Withdrawal and the Effects of Smoking-related Stimuli in Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment studies have demonstrated that current smoking cessation techniques are less
      effective for women. The purpose of this study is to determine the role that gender plays in
      the effectiveness of nicotine replacement therapy. In addition, the purpose of this study is
      to determine whether men and women differ in their response to smoking-related stimuli (e.g.,
      taste or smell of a lit cigarette). Conclusions drawn from this study may help to improve
      cessation interventions for all smokers, particularly women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently,about 70 percent of smokers who try to quit by using smoking cessation treatments
      are unsuccessful. Treatment studies have demonstrated that current smoking cessation
      techniques are less effective for women. There is no clear explanation for this difference,
      but it may involve a differential response to nicotine replacement treatments (NRTs) and/or
      smoking-related stimuli. For women, NRT may be less effective at suppressing withdrawal or
      blunting the effects of smoking during a quit attempt. Women may also be more sensitive to
      smoking-related stimuli, suc has the taste, sight, or smell of cigarette smoke. Tailoring
      treatments to the separate needs of smoker subgroups , such as men and women, my produce
      better cessation outcomes. The purpose of this study is to assess whether men and women
      differ in the their response to NRT (i.e., transdermal nicotine) and smoking-related stimuli.

      Participants in this double-blind, dose-comparison study will complete separate sessions in
      random order.

      Each session will last approximately 6.5 hours and will correspond to a transdermal patch
      dose (0 or 21mg) and cigarette type (denicotinized and nicotinized). Objectively verified
      cigarette abstinence will be required before each session. Sessions will occur at least 48
      hours apart to avoid carryover. At the beginning of each session a patch will be placed on
      the participant's back and at 4, 5, and 6 hours after patch application the participant will
      smoke a cigarette (all identifying marking on the cigarette will be covered for blinding
      purposes). Physiological, subjective, cognitive, and smoking behavior outcomes will be
      collected during study visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Effects</measure>
    <time_frame>6 hours</time_frame>
    <description>The full scale name is the &quot;Urge to smoke&quot; visual analog scale (VAS). It measures self-reported &quot;urge to smoke&quot;. As with any VAS a word or phrase (in this case, &quot;Urge to Smoke&quot; is centered over a horizontal line anchored on the left by &quot;not at all&quot; and on the right by &quot;extremely.&quot; In this study, participants used a mouse to produce a vertical mark on the horizontal line, and the score was the distance of the mark from the left anchor expressed as a percentage of total line length. Thus, the minimum was 0 (&quot;not at all&quot;) and the maximum score was 100 (&quot;extremely&quot;).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Drug Addiction</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>ActiveP/ActiveC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21 mg patch/Nicotine-containing cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PlaceboP/ActiveC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0 mg patch/nicotine-containing cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active P/PlaceboC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21 mg patch/no nicotine cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PlaceboP/PlaceboC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0 mg patch/no nicotine cigarette</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine transdermal system</intervention_name>
    <description>21 mg nicotine transdermal system</description>
    <arm_group_label>ActiveP/ActiveC</arm_group_label>
    <arm_group_label>Active P/PlaceboC</arm_group_label>
    <other_name>Nicoderm CQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine transdermal system</intervention_name>
    <description>Placebo nicotine patch</description>
    <arm_group_label>PlaceboP/ActiveC</arm_group_label>
    <arm_group_label>PlaceboP/PlaceboC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nicotine containing cigarette</intervention_name>
    <description>Nicotine containing cigarette</description>
    <arm_group_label>ActiveP/ActiveC</arm_group_label>
    <arm_group_label>PlaceboP/ActiveC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo cigarette</intervention_name>
    <description>Non nicotine containing cigarette</description>
    <arm_group_label>Active P/PlaceboC</arm_group_label>
    <arm_group_label>PlaceboP/PlaceboC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include, but are not limited to:

        18-50 years of age Smokes 15 cigarettes/day for at least 2 years Healthy (as determined by
        a brief study physical with medical doctor) Displays understanding of cognitive tasks.

        Exclusion Criteria include, but are not limited to:

        History of chronic health problems or psychiatric conditions History of cardiovascular
        disease, low or high blood pressure, seizures, head injuries requiring hospital care,
        peptic ulcer, or diabetes Pregnancy (tested by urinalysis) Scores greater than 17 on the
        Beck Depression Inventory Lack of a high school degree or GED
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E Eissenberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University Department of Psychology, Institute for Drug and Alcohol Studies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University - Clinical Behavioral Pharmacology Laboratory</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2006</study_first_posted>
  <results_first_submitted>November 10, 2011</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2012</results_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine Replacement Therapy</keyword>
  <keyword>Tobacco Smoking</keyword>
  <keyword>Smoking stimuli</keyword>
  <keyword>Gender</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment via media advertisement and flyer. Recruitment began 9/14/2005 and ended 1/30/2008.</recruitment_details>
      <pre_assignment_details>Enrolled (i.e., consented) participants were excluded if they failed to meet safety criteria (e.g., blood pressure) measured after the informed consent was given.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>In this study, overnight abstinent smokers completed four, double-blind laboratory sessions corresponding to a 2x2 design where transdermal nicotine dose (TN, 0 or 21 mg) was crossed with type of cigarette (nicotine-containing [NIC] or not [DENIC]). Cigarettes were smoked 4 hours after TN administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received PlaceboP/Active C</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ActiveP/ActiveC</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PlaceboP/PlaceboC</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ActiveP/PlaceboC</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>In this study, overnight abstinent smokers completed four, double-blind laboratory sessions corresponding to a 2x2 design where transdermal nicotine dose (TN, 0 or 21 mg) was crossed with type of cigarette (nicotine-containing [NIC] or not [DENIC]). Cigarettes were smoked 4 hours after TN administration.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Effects</title>
        <description>The full scale name is the &quot;Urge to smoke&quot; visual analog scale (VAS). It measures self-reported &quot;urge to smoke&quot;. As with any VAS a word or phrase (in this case, &quot;Urge to Smoke&quot; is centered over a horizontal line anchored on the left by “not at all” and on the right by “extremely.” In this study, participants used a mouse to produce a vertical mark on the horizontal line, and the score was the distance of the mark from the left anchor expressed as a percentage of total line length. Thus, the minimum was 0 (“not at all”) and the maximum score was 100 (“extremely”).</description>
        <time_frame>6 hours</time_frame>
        <population>Those who completed all four &quot;arms&quot; of the crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ActiveP/ActiveC</title>
            <description>21 mg patch/Nicotine-containing cigarette</description>
          </group>
          <group group_id="O2">
            <title>PlaceboP/ActiveC</title>
            <description>0 mg patch/nicotine-containing cigarette</description>
          </group>
          <group group_id="O3">
            <title>Active P/PlaceboC</title>
            <description>21 mg patch/no nicotine cigarette</description>
          </group>
          <group group_id="O4">
            <title>PlaceboP/PlaceboC</title>
            <description>0 mg patch/no nicotine cigarette</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Effects</title>
          <description>The full scale name is the &quot;Urge to smoke&quot; visual analog scale (VAS). It measures self-reported &quot;urge to smoke&quot;. As with any VAS a word or phrase (in this case, &quot;Urge to Smoke&quot; is centered over a horizontal line anchored on the left by “not at all” and on the right by “extremely.” In this study, participants used a mouse to produce a vertical mark on the horizontal line, and the score was the distance of the mark from the left anchor expressed as a percentage of total line length. Thus, the minimum was 0 (“not at all”) and the maximum score was 100 (“extremely”).</description>
          <population>Those who completed all four &quot;arms&quot; of the crossover study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="24.7"/>
                    <measurement group_id="O2" value="23.1" spread="24.5"/>
                    <measurement group_id="O3" value="25.6" spread="28.8"/>
                    <measurement group_id="O4" value="24.2" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ActiveP/ActiveC</title>
          <description>21 mg patch/Nicotine-containing cigarette</description>
        </group>
        <group group_id="E2">
          <title>PlaceboP/ActiveC</title>
          <description>0 mg patch/nicotine-containing cigarette</description>
        </group>
        <group group_id="E3">
          <title>Active P/PlaceboC</title>
          <description>21 mg patch/no nicotine cigarette</description>
        </group>
        <group group_id="E4">
          <title>PlaceboP/PlaceboC</title>
          <description>0 mg patch/no nicotine cigarette</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Eissenberg</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804.827.4617</phone>
      <email>teissenb@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

